Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Most muscle-related safety concepts (myopathy/rhabdomyolysis, symptoms, and interaction-related increased risk) are broadly consistent with the label excerpts, but several specific/clinical-emphasis statements are not directly supported by the provided label text (e.g., urine color as an urgent symptom, fever/unwell triage as urgent, exercise disruption phrasing, and “often noticed” timing).
Category Scores
Accurate Statements
Lipitor can cause muscle pain, tenderness, or weakness.
Supported by Section 5.1 (Atorvastatin occasionally causes myopathy; therapy temporarily withheld/discontinued in any patient with an acute, serious condition suggestive of a myopathy).
In rare cases, Lipitor can involve a serious muscle injury called rhabdomyolysis.
Supported by Section 5.1 (Rare cases of rhabdomyolysis with acute renal failure secondary to myoglobinuria have been reported).
Risk of Lipitor muscle side effects is higher with certain drug interactions.
Supported by Section 5.1 and Section 7 (risk of myopathy increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors).
Unsupported Statements
Lipitor (atorvastatin) can cause side effects that make exercise feel unsafe or impractical.
No label excerpt supports that statin side effects make exercise feel unsafe/impractical.
In some cases, Lipitor side effects are significant enough to cause people to stop workouts temporarily.
The label excerpt supports withholding/discontinuing therapy in certain conditions suggestive of myopathy, but does not support that side effects cause people to stop workouts.
Muscle pain, tenderness, or weakness with sometimes elevated muscle enzymes.
Provided excerpts mention myopathy/rhabdomyolysis and liver transaminase testing, but do not mention muscle enzyme elevation.
Symptoms of Lipitor-related muscle injury include muscle pain, tenderness, or weakness.
The provided excerpt indicates myopathy is suggested by an acute, serious condition, but does not list specific symptom wording such as tenderness/weakness.
Dark or tea-colored urine can be a warning sign of severe muscle breakdown associated with Lipitor.
The provided excerpt mentions myoglobinuria secondary to rhabdomyolysis but does not connect it to urine color as a warning sign.
Dark or tea-colored urine is an urgent symptom.
The excerpt does not specify urine-color urgency or triage language.
Muscle aches, soreness beyond what is normally felt after activity, weakness, or pain that does not improve with rest are side effects most likely to disrupt exercise.
The label excerpt does not characterize muscle symptoms in those terms or link them to being most likely to disrupt exercise.
If fever or feeling very unwell occurs with severe muscle symptoms while taking Lipitor, it should be treated as urgent.
The provided label excerpt does not include fever/feeling unwell guidance as an urgent triage.
New, unusual, or worsening muscle pain or weakness after starting Lipitor or after a dose increase warrants stopping workouts and getting medical advice.
The label excerpt supports temporarily withholding or discontinuing LIPITOR for an acute, serious condition suggestive of myopathy, but does not support stopping workouts or provide this dose-timing phrasing for symptom-based action.
Muscle side effects can occur any time during Lipitor treatment.
No label excerpt provides timing such as “any time” during treatment.
Muscle side effects are often noticed after starting Lipitor therapy or after dose changes.
No label excerpt supports this timing/likelihood statement.
Risk of Lipitor muscle side effects is higher with higher statin doses.
The provided excerpts support increased risk with concomitant drugs and higher atorvastatin doses in context of drug interactions, but do not state broadly that higher statin doses increase risk.
Risk of Lipitor muscle side effects is higher with some medical conditions.
The excerpt references risk factors predisposing to renal failure secondary to rhabdomyolysis and “risk factor predisposing,” but does not enumerate medical conditions as a general statement.
When symptoms occur, muscle enzyme levels may be checked and treatment may be adjusted if needed.
The provided label excerpt includes liver function testing recommendations (transaminases), but does not mention checking muscle enzyme levels or the specific management described for muscle symptoms.
Contradictions
Low
AI Statement
Dark or tea-colored urine is an urgent symptom.
Label Reference
No direct contradiction; severity/urgency triage wording is not present in the provided excerpts.
Important Omissions
Specific label language instructing that LIPITOR should be temporarily withheld or discontinued in patients with an acute, serious condition suggestive of myopathy and/or having a risk factor predisposing to renal failure secondary to rhabdomyolysis.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements provide practical triage/exercise-stopping guidance and symptom descriptors (urine color, fever/unwell urgency, action after dose changes) that are not supported by the provided label excerpts, which could lead to miscalibrated patient decision-making relative to on-label guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple muscle-symptom and urgency/timing/action statements are not directly supported by the provided prescribing information excerpts (especially urine color as urgent, fever triage, and exercise-stopping guidance).
Suggested Improvement
Align wording to on-label guidance in Section 5.1: describe rare rhabdomyolysis and myopathy risk, and state that LIPITOR should be temporarily withheld or discontinued in patients with an acute, serious condition suggestive of myopathy or those at risk for renal failure secondary to rhabdomyolysis, avoiding unsupported details (urine color urgency, fever triage, exercise-specific actions, and timing/likelihood claims).